Alfentanil is named as an intervention in 2 current clinical trials in our China and Taiwan registers. 1 is recruiting patients now. The most common phase is Phase 4. The sponsor with the most trials is Zhongshan Ophthalmic Center, Sun Yat-sen University (1). The most-studied condition is Pediatric Anesthesia. The EU clinical trials register (CTIS) separately lists 3 authorised or ongoing trials.
Alfentanil was first approved in the US on 29 Dec 1986.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
EEG and Pain Monitor Data Under Anesthesia to Study Pharmacodynamic Effects of Opioids and Sedatives
NCT07211828 · ClinicalTrials.gov ↗ · Sedation and Analgesia, Cholangiopancreatography, Endoscopic Retrograde, Anesthesia, General
|
Not applicable | Recruiting | Chi Kwan Fung | Taiwan |
|
Effective Dose of Alfentanil Combined With Propofol for Laryngeal Mask Airway Insertion in Children
NCT07581665 · ClinicalTrials.gov ↗ · Pediatric Anesthesia, Airway Management, General Anesthesia
|
Phase 4 | Not yet open | Zhongshan Ophthalmic Center, Sun Yat-sen University | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Alfentanil. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
Patient-Controlled Anesthesia for endoscopic Procedural Sedation – PCAPS study
2025-524859-31-00 · Digestive System Diseases
|
Phase 4 | Authorised | Karolinska Institutet | Sweden |
|
Efficacy, Safety, and Patient Satisfaction of Patient-Controlled Remimazolam Sedation in Outpatient Colonoscopy: A randomized controlled trial.
2026-525809-13-00 · Digestive System Diseases
|
Phase 4 | Authorised | Region Hovedstaden | Denmark |
|
Comparison of morphine and alfentanil in the emergency treatment of severe acute pain in the pre-hospital setting
2025-522817-50-00 · CTIS ↗ · Population Characteristics
|
Phase 4 | Authorised | CHU De Martinique | France |
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
1 single-substance product containing Alfentanil on the HPRA medicines list.
No entry for Alfentanil in the EMA, FDA or German BfArM shortage lists we track.
| Lead sponsor | Trials |
|---|---|
| Zhongshan Ophthalmic Center, Sun Yat-sen University | 1 |
| Chi Kwan Fung | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 1 | 0 |
| Clinical trials in Taiwan | 1 | 1 |
| EU register (CTIS) | 3 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
2 current trials in our China and Taiwan registers name Alfentanil as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in Taiwan. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Zhongshan Ophthalmic Center, Sun Yat-sen University (1) and Chi Kwan Fung (1). The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 1 single-substance product containing Alfentanil, for example Rapifen 500 micrograms/ml solution for injection or infusion (Piramal Critical Care B.V.). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Alfentanil has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Alfentanil works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Alfentanil works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Alfentanil (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.